Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 3 of 18
Next
>>
>
51 to 75 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
Hs 578T	Sirolimus	3		flat	flat	Hs578T rapamycin 3	8	2.836	Inf	0.675	0.309	0.0	0.675	0.01	-1.79	1.0	0.691	Inf	0.604	0.621	0.0	0.604	0.01	-3.02	1.0	0.621
HCC1806	AZD-6482	2	72	flat	flat	HCC1806 AZD6482 0 2 72	8	2.833	Inf	1.0	0.00136	0.0	1.0	0.01	-0.0062	1.0	0.999	Inf	1.01	0.998	0.0	1.01	0.01	-0.00512	1.0	0.998
Hs 578T	AZD-6482	3		sigmoid	sigmoid	Hs578T AZD6482 3	8	2.832	6.09	0.667	0.0547	24.1	-1.0	0.799	0.989	1.5e-06	NA	5.12	0.597	0.93	5.12	0.0	0.861	0.985	3.33e-06	NA
HCC1806	MK2206	2	72	sigmoid	sigmoid	HCC1806 MK-2206 0 2 72	8	2.831	51.9	0.823	0.0489	320.0	-0.668	0.467	0.981	7.01e-06	NA	Inf	0.769	0.934	4.46	0.507	0.566	0.976	1.45e-05	NA
Hs 578T	GDC-0980	3		sigmoid	sigmoid	Hs578T apitolisib 3	8	2.831	0.243	0.145	0.315	0.19	0.112	1.02	0.998	4.02e-09	NA	0.179	0.206	0.665	0.114	0.196	1.09	0.999	9.76e-10	NA
Hs 578T	Trametinib	3		sigmoid	sigmoid	Hs578T trametinib 3	8	2.830	0.0128	0.0657	0.644	0.0112	0.0447	0.702	0.998	4.02e-09	NA	0.00864	0.168	0.366	0.00512	0.157	0.722	0.998	5.57e-09	NA
HCC1806	Dactolisib	2	72	sigmoid	sigmoid	HCC1806 dactolisib 0 2 72	8	2.828	0.145	-0.0528	0.433	0.401	-0.401	0.578	0.986	2.83e-06	NA	0.0977	0.121	0.559	0.0929	0.0151	0.619	0.986	2.47e-06	NA
HCC1806	Buparlisib	2	72	sigmoid	sigmoid	HCC1806 buparlisib 0 2 72	8	2.827	0.759	-0.346	0.221	0.937	-0.392	2.75	1.0	2.72e-11	NA	0.69	0.0423	0.803	0.674	0.033	2.99	0.999	1.17e-09	NA
HCC1806	KIN001-244	2	72	flat	flat	HCC1806 KIN001-244 0 2 72	8	2.827	Inf	0.986	0.0229	0.0	0.986	0.01	-0.0574	1.0	0.98	Inf	0.981	0.968	0.0	0.981	0.01	-0.0553	1.0	0.972
HCC1806	BX-912	2	72	sigmoid	sigmoid	HCC1806 BX-912 0 2 72	8	2.825	0.992	0.159	0.14	0.888	0.141	2.99	0.999	3.32e-09	NA	0.894	0.214	0.854	0.753	0.205	3.07	0.997	2.86e-08	NA
Hs 578T	TGX221	3		sigmoid	sigmoid	Hs578T TGX-221 3	8	2.818	24.2	0.885	0.0148	88.9	-1.0	0.843	0.958	7.66e-05	NA	23.4	0.846	0.98	23.4	0.0	0.862	0.953	0.000103	NA
HCC1806	AZD8055	2	72	sigmoid	sigmoid	HCC1806 AZD8055 0 2 72	8	2.817	Inf	0.546	0.24	0.0517	0.535	1.19	0.995	1.31e-07	NA	0.521	0.484	0.716	0.0427	0.471	1.15	0.996	7.15e-08	NA
HCC1806	XL147	2	72	flat	flat	HCC1806 pilaralisib 0 2 72	8	2.817	Inf	1.02	0.000975	0.0	1.02	0.01	-4.46e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000109	1.0	1.0
Hs 578T	PIK-93	3		sigmoid	sigmoid	Hs578T PIK-93 3	8	2.816	2.36	0.412	0.0884	2.23	0.033	1.2	0.994	1.87e-07	NA	1.89	0.375	0.897	1.42	0.149	1.24	0.991	8.33e-07	NA
HCC1806	AS605240	2	72	sigmoid	sigmoid	HCC1806 AS-605240 0 2 72	8	2.813	Inf	0.913	0.0124	0.569	0.913	2.8	0.936	0.000261	NA	Inf	0.883	0.983	0.559	0.882	2.81	0.931	0.000333	NA
Hs 578T	PI103	3		sigmoid	sigmoid	Hs578T PI-103 3	8	2.807	0.321	0.175	0.26	0.231	0.163	1.21	0.991	8.05e-07	NA	0.232	0.225	0.729	0.145	0.239	1.39	0.986	2.82e-06	NA
Hs 578T	BX-912	3		sigmoid	sigmoid	Hs578T BX-912 3	8	2.805	1.04	0.0121	0.125	1.09	-0.0661	2.36	0.992	4.22e-07	NA	0.936	0.148	0.883	0.841	0.116	2.45	0.982	5.7e-06	NA
HCC1806	Sirolimus	1	72	sigmoid	sigmoid	HCC1806 rapamycin 0 1 72	8	2.796	1.35	0.775	0.187	0.00019	0.706	0.1	0.661	0.039	NA	1.05	0.717	0.76	1e-05	0.657	0.1	0.68	0.0328	NA
HCC1806	ZSTK474	2	72	sigmoid	sigmoid	HCC1806 ZSTK474 0 2 72	8	2.794	Inf	0.613	0.036	1.16	0.61	5.0	0.99	1.1e-06	NA	Inf	0.548	0.958	1.12	0.545	4.88	0.985	3.14e-06	NA
HCC1806	WYE-125132	1	72	sigmoid	sigmoid	HCC1806 WYE-132 0 1 72	8	2.790	0.603	0.466	0.292	0.0448	0.45	0.883	0.997	3.72e-08	NA	0.226	0.42	0.663	0.0335	0.402	0.855	0.996	8.79e-08	NA
HCC1806	Everolimus	1	72	sigmoid	sigmoid	HCC1806 everolimus 0 1 72	8	2.786	Inf	0.784	0.183	0.000282	0.748	0.187	0.86	0.00277	NA	Inf	0.727	0.765	0.00022	0.729	0.377	0.879	0.00177	NA
HCC1806	Pictilisib	1	72	sigmoid	sigmoid	HCC1806 pictilisib 0 1 72	8	2.782	11.7	0.79	0.049	43.7	-1.0	0.831	0.811	0.00677	NA	11.3	0.734	0.935	11.3	0.0	0.849	0.773	0.0116	NA
HCC1806	GDC-0980	2	72	sigmoid	sigmoid	HCC1806 apitolisib 0 2 72	8	2.781	1.32	0.355	0.148	0.746	0.241	1.15	0.995	1.49e-07	NA	0.947	0.339	0.832	0.475	0.292	1.27	0.993	2.95e-07	NA
HCC1806	CAL-101	2	72	flat	flat	HCC1806 idelalisib 0 2 72	8	2.779	Inf	1.02	-0.00985	0.0	1.02	0.01	-0.594	1.0	1.01	Inf	1.03	1.01	0.0	1.03	0.01	-0.588	1.0	1.02
HCC1806	Alpelisib	1	72	flat	flat	HCC1806 alpelisib 0 1 72	8	2.771	Inf	0.918	0.0583	0.0	0.918	0.01	-0.337	1.0	0.94	Inf	0.891	0.921	0.0	0.891	0.01	-0.351	1.0	0.919

|<
<<
Previous
Page 3 of 18
Next
>>
>
51 to 75 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)